While stock splits are far from easy to predict, two names stand out for their potential to do so going forward. Those stocks ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

Eli Lilly (NYSE:LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth stories—and it’s not just hype. Powered by blockbuster drugs for diabetes ...